Cargando…
Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362548/ https://www.ncbi.nlm.nih.gov/pubmed/28403580 http://dx.doi.org/10.18632/oncotarget.15755 |
| _version_ | 1782516975523594240 |
|---|---|
| author | Pires, Eusebio S. D'Souza, Ryan S. Needham, Marisa A. Herr, Austin K. Jazaeri, Amir A. Li, Hui Stoler, Mark H. Anderson-Knapp, Kiley L. Thomas, Theodore Mandal, Arabinda Gougeon, Alain Flickinger, Charles J. Bruns, David E. Pollok, Brian A. Herr, John C. |
| author_facet | Pires, Eusebio S. D'Souza, Ryan S. Needham, Marisa A. Herr, Austin K. Jazaeri, Amir A. Li, Hui Stoler, Mark H. Anderson-Knapp, Kiley L. Thomas, Theodore Mandal, Arabinda Gougeon, Alain Flickinger, Charles J. Bruns, David E. Pollok, Brian A. Herr, John C. |
| author_sort | Pires, Eusebio S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5362548 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53625482017-04-24 Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors Pires, Eusebio S. D'Souza, Ryan S. Needham, Marisa A. Herr, Austin K. Jazaeri, Amir A. Li, Hui Stoler, Mark H. Anderson-Knapp, Kiley L. Thomas, Theodore Mandal, Arabinda Gougeon, Alain Flickinger, Charles J. Bruns, David E. Pollok, Brian A. Herr, John C. Oncotarget Correction Impact Journals LLC 2017-02-27 /pmc/articles/PMC5362548/ /pubmed/28403580 http://dx.doi.org/10.18632/oncotarget.15755 Text en Copyright: © 2017 Pires et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Pires, Eusebio S. D'Souza, Ryan S. Needham, Marisa A. Herr, Austin K. Jazaeri, Amir A. Li, Hui Stoler, Mark H. Anderson-Knapp, Kiley L. Thomas, Theodore Mandal, Arabinda Gougeon, Alain Flickinger, Charles J. Bruns, David E. Pollok, Brian A. Herr, John C. Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| title | Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| title_full | Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| title_fullStr | Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| title_full_unstemmed | Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| title_short | Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| title_sort | correction: membrane associated cancer-oocyte neoantigen sas1b/ovastacin is a candidate immunotherapeutic target for uterine tumors |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362548/ https://www.ncbi.nlm.nih.gov/pubmed/28403580 http://dx.doi.org/10.18632/oncotarget.15755 |
| work_keys_str_mv | AT pireseusebios correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT dsouzaryans correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT needhammarisaa correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT herraustink correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT jazaeriamira correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT lihui correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT stolermarkh correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT andersonknappkileyl correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT thomastheodore correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT mandalarabinda correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT gougeonalain correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT flickingercharlesj correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT brunsdavide correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT pollokbriana correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors AT herrjohnc correctionmembraneassociatedcanceroocyteneoantigensas1bovastacinisacandidateimmunotherapeutictargetforuterinetumors |